business
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results
Key takeaways
- Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results Fatima Gulzar Sun, June 14, 2026 at 1:06 AM GMT+7 1 min read ABUS MRNA Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the
- 10 Most Profitable Small Cap Stocks to Buy.
- On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna.
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results Fatima Gulzar Sun, June 14, 2026 at 1:06 AM GMT+7 1 min read ABUS MRNA Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the
10 Most Profitable Small Cap Stocks to Buy.
On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of the increase in its share of a noncontingent settlement payment through Genevant Sciences.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop